mRNA疫苗原型可诱导对多种食物过敏的保护性抗体反应
Eating without fear: A single vaccine shows promise against multiple food allergies
丹麦技术大学团队在《自然·通讯》发表的研究报道了一种mRNA疫苗的早期概念验证工作:该疫苗以合成变应原为核心,设计目标是让免疫系统产生可中和多种结构相似食物变应原的保护性IgG抗体。
According to U.N. figures, more than 220 million people worldwide suffer from food allergies, which cause the body to perceive an otherwise harmless protein in food as dangerous. As a result, the immune system launches an attack on the protein, which in the worst cases can be life-threatening.
In the only treatment currently capable of potentially curing people's allergies, patients are exposed over several years—via injections or tablets—to increasing amounts of the protein (allergen) they cannot tolerate, so the body gradually gets used to it.
However, due to the hassle and discomfort of the treatment, many people choose "simply" to avoid the substances to which they are allergic, as well as anything that might trigger a cross-reaction.
A Trojan horse
As an alternative, researchers at DTU have developed a vaccine that contains a synthetic allergen. The allergen shares common features with several related and widespread allergens found, for example, in peaches and certain nuts.
The vaccine is designed to reprogram the body's immune system so that, upon encountering these related allergens, it produces protective antibodies that can recognize and block the allergens before they have a chance to trigger an allergic reaction.
"The idea is that if you are allergic to several different things, all of which have roughly the same molecular structure, we can take this structure and produce an artificial allergen, which we then incorporate into a vaccine," explains Associate Professor Esperanza Rivera de Torre from DTU Bioengineering.
The researchers are using an mRNA vaccine like those we came to know during the COVID-19 pandemic.
"We use the mRNA as a Trojan horse: Instead of giving the patient the actual allergen and building up the body's tolerance to it, we use the vaccine to give the body instructions on how to handle the allergen correctly, thereby avoiding an allergic reaction. My hope is that patients will be able to eat whatever they like without having to check the ingredients list," she explains.
Good protection
The researchers have studied the effect of the vaccine in both healthy and allergic mice in a study whose promising results were published in Nature Communications.
After the first dose of the vaccine, the healthy mice produced large quantities of protective antibodies. After three doses administered at three-week intervals, the mice were exposed to a range of the allergens against which the vaccine is designed to provide protection. The study showed that the vaccination had elicited a strong antibody response, providing broad coverage against the allergens.
In the allergic mice, the researchers also recorded a marked increase in the production of antibodies that protect against the range of allergens, while virtually no side effects of the vaccine were observed. However, it did not provide full protection against anaphylaxis at the concentration and number of doses tested.
The researchers also carried out laboratory experiments using blood samples from both allergic patients and the vaccinated mice. The analyses show that the protective antibodies produced by the mice were able to reduce allergic reactions in the patient samples.
"If you can induce such antibody responses in mice, then there is also a very good chance that you can do so in humans. And if they protect the mice against allergic reactions, then there is also a good chance that they will provide protection in humans," explains Ph.D. student and lead author of the article Mark Møiniche.
All in all, the researchers' work on the vaccine constitutes a proof of concept—that is, evidence that the idea is technically feasible. They are now working, among other things, on refining the lipid bubbles in which the immune-activating allergen is encapsulated before it is incorporated into the vaccine.
"You can swap out different parts of the lipids, depending on how you want to tweak the immune system to elicit a specific response or perhaps avoid a particular response," Møiniche explains.
The researchers are also planning studies on a larger group of mice to, among other things, gain a better understanding of how often the vaccine should be administered, and in what doses, to achieve full protection—including against anaphylaxis.
The current vaccine targets several related allergens that are particularly widespread in southern Europe, and which can cause cross-reactions upon consumption of a wide range of fruits. However, the researchers expect that the concept can be applied to other classes of cross-reactive allergens.
They are therefore also working on developing a consensus allergen that can provide protection against exposure to another group of allergens, found, for example, in apples, carrots and hazelnuts.
The researchers' overarching aim is to generate the data required to obtain approval to test the vaccine in humans.
Publication details
Mark Møiniche et al., An mRNA-delivered consensus allergen induces a neutralizing IgG response against food and pollen allergens, Nature Communications (2026). DOI: 10.1038/s41467-026-69134-4
Journal information: Nature Communications
Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Eating without fear: A single vaccine shows promise against multiple food allergies (2026, November 16) retrieved 16 November 2026 from https://medicalxpress.com/news/2026-11-vaccine-multiple-food-allergies.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com